A method for synthesizing chiral 1,3-benzoxazine derivatives

Chiral 1,3-benzoxazines were solved by catalyzing the asymmetric [4+2]-cycloaddition reaction of 2-hydroxyphenylallyl alcohol and 1,3,5-triazine compounds by iridium catalyst. The problem of lag in derivative synthesis methods has achieved high-efficiency and enantioselective synthesis under high-efficiency and mild conditions.

CN116589426BActive Publication Date: 2024-11-19CHANGZHOU UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310407704.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-04-14
Publication Date
2024-11-19
Estimated Expiration
2043-04-14

AI Technical Summary

Technical Problem

The prior art has failed to effectively solve the asymmetric [4+2] cycloaddition reaction of chiral 1,3-benzooxazine derivatives, resulting in a lag in its synthesis method, limiting further research.

Method used

Iridium catalyst is used to catalyze the asymmetric [4+2]-cycloaddition reaction between 2-hydroxyphenylallyl alcohol and 1,3,5-triazine compounds. High region is achieved through designing catalytic system and conditional screening. and enantioselectively synthesize chiral 1,3-benzooxazine derivatives.

Benefits of technology

This method has good substrate applicability, mild reaction conditions, high regioselectivity and enantioselectivity, and achieves efficient synthesis of chiral 1,3-benzooxazine derivatives.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116589426B_ABST
    Figure CN116589426B_ABST
Patent Text Reader

Abstract

The invention discloses a method for synthesizing chiral 1,3-benzoxazine derivatives. Specifically, a method for preparing a series of chiral 1,3-benzoxazine derivatives by combining an iridium catalyst and a chiral ligand, catalyzing asymmetric [4+2]-cycloaddition reaction of racemic 2-hydroxyphenyl allyl alcohol and 1,3,5-triazine compounds, and the method belongs to the field of organic synthesis. The specific operation steps are: under argon protection, an iridium catalyst and a chiral ligand are added to a reaction tube, followed by adding 2-hydroxyphenyl allyl alcohol, 1,3,5-triazine compounds and additives, and then reacting at 25°C, until the reaction is complete, purifying and separating, and obtaining chiral 1,3-benzoxazine derivatives. The method has the advantages of good substrate applicability, mild reaction conditions, high regioselectivity and enantioselectivity.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of organic synthesis, and specifically relates to a method for synthesizing chiral 1,3-benzoxazine derivatives. Background Art

[0002] 1,3-Benzoxazine derivatives are a common class of organic synthesis intermediates, widely present in natural products and various pharmaceutical intermediates. Small molecule active drugs such as CX-614 and Seclazone all have 1,3-benzoxazine skeleton units. Catalytic asymmetric hetero[4+2] cycloaddition reaction is the most efficient and convenient method to construct benzo heterocycles. However, through literature research, only some works have been reported on the synthesis of non-chiral 1,3-benzoxazine derivatives (see: Cheng, X.; Zhou, S.-J.; Xu, G.-Y.; Wang, L.; Yang, Q.-Q.; Xuan, J. Adv. Synth. Catal. 2020, 362, 523-527.). So far, there is no method for synthesizing chiral 1,3-benzoxazine derivatives by asymmetric [4+2] cycloaddition reaction. The lag in asymmetric synthesis methods has seriously restricted further research on chiral 1,3-benzoxazine derivatives.

[0003] In view of this, based on our previous work, we continued to look for methods to develop efficient methods for constructing chiral 1,3-benzoxazine compounds starting from readily available substrates. Therefore, we designed a catalytic system and screening conditions to achieve the iridium-catalyzed asymmetric [4+2]-cycloaddition reaction of racemic 2-hydroxyphenylallyl alcohol and 1,3,5-triazine compounds to prepare a series of chiral 1,3-benzoxazine derivatives. This method has the advantages of good substrate applicability, mild reaction conditions, high regioselectivity and enantioselectivity. Summary of the invention

[0004] The present invention utilizes an asymmetric [4+2]-cycloaddition strategy to provide a method for synthesizing chiral 1,3-benzoxazine derivatives with high regio- and enantioselectivity using readily available 2-hydroxyphenyl allyl alcohol and 1,3,5-triazine compounds as reaction raw materials.

[0005] In order to achieve the purpose of the present invention, the technical solution adopted is:

[0006] A method for synthesizing chiral 1,3-benzoxazine derivatives, characterized in that: under the catalytic action of an iridium catalyst, racemic 2-hydroxyphenyl allyl alcohol and a 1,3,5-triazine compound undergo an asymmetric [4+2]-cycloaddition reaction to prepare chiral 1,3-benzoxazine derivatives. The racemic 2-hydroxyphenyl allyl alcohol has the structural formula:

[0007]

[0008] Wherein, R can be methyl, methoxy or halogen.

[0009] Furthermore, the method is carried out according to the following steps: under the protection of argon, the iridium catalyst and the chiral ligand are dissolved in a solvent and placed in a sealed tube, and stirred to fully coordinate the iridium and the chiral ligand in the iridium catalyst. Subsequently, 2-hydroxyphenyl allyl alcohol, 1,3,5-triazine compound and additives are added to the sealed tube, the argon is replaced, and then fully reacted at 0-40°C (generally about 12 hours, low temperature reaction is slow, high temperature reaction is fast, but too high temperature is not conducive to stereoselectivity, the most suitable temperature is 25°C), and then purified to obtain chiral 1,3-benzoxazine derivatives.

[0010] Furthermore, the structural formula of the 1,3,5-triazine compound is:

[0011]

[0012] Wherein, Ar is phenyl or p-methoxyphenyl.

[0013] The specific reaction equation is as follows (Scheme 1):

[0014]

[0015] Scheme 1. Reaction equation

[0016] Furthermore, the molar ratio of the 2-hydroxyphenyl allyl alcohol to the 1,3,5-triazine compound is 3:1-1:1, wherein when the molar ratio is 2:1, the yield is the highest.

[0017] Furthermore, the amount of the iridium catalyst used is 2%-4% (more preferably 4%) of the molar equivalent of 2-hydroxyphenyl allyl alcohol.

[0018] Furthermore, the chiral phosphoramidite ligand L is in S-configuration and has the structural formula The usage amount is 200-400% of the molar amount of iridium catalyst.

[0019] Furthermore, the additive is trifluoroacetic acid, and its equivalent is 80-200% of the equivalent of 2-hydroxyphenyl allyl alcohol. When its catalytic amount is 100%, the highest yield is achieved.

[0020] Compared with the prior art, the present invention achieves the following beneficial effects:

[0021] The method of the present invention utilizes an asymmetric [4+2]-cycloaddition strategy to provide a method for synthesizing chiral 1,3-benzoxazine derivatives with high regio- and enantio-selectivity using easily prepared 2-hydroxyphenyl allyl alcohol and 1,3,5-triazine compounds as reaction raw materials. The method has the advantages of good substrate applicability, mild reaction conditions, high regio- and enantio-selectivity. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1 is the hydrogen spectrum of compound 3aa prepared in Example;

[0023] Figure 2 is the carbon spectrum of compound 3aa prepared in Example;

[0024] Figure 3 The high performance liquid chromatogram of the racemic sample 3aa prepared in Example (Racemic sample 3aa: HPLC (Daicel Chiralpak OJ-H column (hexane / iPrOH=70:30, flow rate: 1.0mL / min, λ=215nm));

[0025] Figure 4 is the HPLC chromatogram of the chiral product 3aa;

[0026] Figure 5 This is the high-resolution mass spectrum of the product 3aa. DETAILED DESCRIPTION

[0027] The present invention will be further described below in conjunction with examples, but is not limited thereto (mol % and eq in the following examples are all calculated results relative to 2-hydroxyphenyl allyl alcohol).

[0028] Implementation Example 1:

[0029] Synthesis of (3aa):

[0030]

[0031] Under argon protection, 1,5-cyclooctadiene iridium chloride dimer (5.3 mg, 4 mol%), (S)-L (16.6 mg, 16 mol%) and dichloroethane (1.5 mL) were added to the reaction tube and stirred at room temperature for 10 minutes. Subsequently, 1a (0.2 mmol, 30.0 mg, 1 eq.), 2a (0.1 mmol, 44.6 mg) and TFA (1.0 eq.) were added. The tube was then sealed and the reaction was allowed to react at 25 ° C for 24 h. After treatment, the crude product was purified by TLC preparation plate to obtain 3aa (29.5 mg, 93% ee, yield: 53%). 11H NMR (400 MHz, CDCl3) δ 7.30 - 7.26 (m, 2H), 7.16 (ddd, J = 8.5, 7.1, 1.8 Hz, 1H), 6.95 (dd, J = 7.6, 1.8 Hz, 1H), 6.90 - 6.83 (m, 4H), 6.02 (ddd, J = 17.2, 10.2, 4.6 Hz, 1H), 5.24 (dt, J = 10.2, 1.6 Hz, 1H), 4.98 (dt, J = 17.2, 1.6 Hz, 1H), 4.93 (d, J = 10.1 Hz, 1H), 4.67 (dd, J = 10.1, 1.7 Hz, 1H), 4.17 (dd, J = 4.5, 2.0 Hz, 1H), 3.96 (d, J = 13.4 Hz, 1H), 3.80 (s, 3H), 3.78 (d, J = 13.4 Hz, 1H). 13 13C NMR (100 MHz, CDCl3) δ 159.0, 154.1, 140.3, 130.4, 130.1, 129.8, 128.1, 120.5, 120.3, 117.7, 116.8, 113.9, 78.0, 58.6, 55.41, 55.39. HRMS (ESI) m / z calculated for C 18 H 20 NO2 [M + H] + : 282.1489, found: 282.1496. HPLC: Daicel Chiralpak OJ - H column (hexane / iPrOH = 70:30, flow rate: 1.0 mL / min, λ = 215 nm, t R (major) = 9.28 min, t R (minor) = 11.83 min. ee = 93%.

[0032] Example 2:

[0033] (Synthesis of (3ab)):

[0034]

[0035] Under argon protection, 1,5-cyclooctadiene iridium chloride dimer (5.3 mg, 4 mol%), (S)-L (16.6 mg, 16 mol%) and dichloroethane (1.5 mL) were added to the reaction tube and stirred at room temperature for 10 minutes. Subsequently, 1b (0.2 mmol, 33.0 mg, 1 eq.), 2a (0.1 mmol, 44.6 mg) and TFA (1.0 eq.) were added. The tube was then sealed and the reaction was allowed to react at 25 ° C for 24 h. After treatment, the crude product was purified by TLC preparation plate to obtain 3ab (33.5 mg, 94% ee, yield: 57%). 1 H NMR (400MHz, CDCl3) δ7.31-7.26(m,2H),6.97(dd,J=8.3,2.2Hz,1H),6.89-6.84(m,2H),6 .78-6.72(m,2H),6.01(ddd,J=17.3,10.3,4.7Hz,1H),5.22(dt,J=10.3,1.7Hz,1H),5.00( dt,J=17.2,1.7Hz,1H),4.89(d,J=10.0Hz,1H),4.64(dd,J=10.0,1.6Hz,1H),4.13(dd,J= 4.7,2.0Hz,1H),3.95(d,J=13.4Hz,1H),3.80(s,3H),3.78(d,J=13.5Hz,1H),2.25(s,3H). 13 C NMR (101MHz, CDCl3) δ159.0,151.8,140.4,130.5,130.1,129.9,129.4,128. 8,120.2,117.4,116.5,113.9,78.0,58.7,55.40,55.38,20.8.HRMS(ESI)m / z calculated for C 19 H 22 NO2[M+H] + :296.1645,found:296.1653.Optical Rotation:[α] D 25 =+36.1(c=0.1,CHCl3).HPLC:Daicel Chiralpak OJ-H column(hexane / iPrOH=90:10, flow rate:0.7mL / min,λ=215nm,t R (major)=12.54min,t R (minor) = 13.98min.ee = 94%. Implementation Example 3:

[0036] Synthesis of (3ac):

[0037]

[0038] Under argon protection, 1,5-cyclooctadiene iridium chloride dimer (5.3 mg, 4 mol%), (S)-L (16.6 mg, 16 mol%) and dichloroethane (1.5 mL) were added to the reaction tube and stirred at room temperature for 10 minutes. Subsequently, 1c (0.2 mmol, 46.0 mg, 1 eq.), 2a (0.1 mmol, 44.6 mg) and TFA (1.0 eq.) were added. The tube was then sealed and the reaction was allowed to react at 25 ° C for 24 h. After treatment, the crude product was purified by TLC preparation plate to obtain 3ac (44.0 mg, 94% ee, yield: 61%). 1 H NMR (400MHz, CDCl3) δ7.28-7.24(m,3H),7.07(dd,J=2.4,0.7Hz,1H),6.90-6.84(m,2H) ,6.74(d,J=8.7Hz,1H),5.98(ddd,J=17.3,10.3,4.6Hz,1H),5.26(dt,J=10.3,1.6Hz,1H ),4.97(dt,J=17.3,1.5Hz,1H),4.89(d,J=10.2Hz,1H),4.67(dd,J=10.1,1.7Hz,1H),4 .14(dd,J=4.5,2.1Hz,1H),3.92(d,J=13.3Hz,1H),3.80(s,3H),3.73(d,J=13.3Hz,1H). 13 C NMR (100MHz, CDCl3) δ159.1,153.2,139.6,132.1,131.1,130.1,130.0,122.4,118.7,118.3,114.0,112.1,78.1,58.3,55.44,55.39.HRMS (ESI) m / z calculated for C 18 H 19 BrNO2[M+H] + :360.0594, found: 360.0601. HPLC: Daicel Chiralpak IA column (hexane / iPrOH=99:1, flow rate: 0.7mL / min, λ=215nm, t R (major)=7.35min,t R (minor) = 7.74min.ee = 94%.

[0039] Implementation Example 4:

[0040] Synthesis of (3ad):

[0041]

[0042] Under argon protection, 1,5-cyclooctadiene iridium chloride dimer (5.3 mg, 4 mol%), (S)-L (16.6 mg, 16 mol%) and dichloroethane (1.5 mL) were added to the reaction tube and stirred at room temperature for 10 minutes. Subsequently, 1d (0.2 mmol, 46.0 mg, 1 eq.), 2a (0.1 mmol, 44.6 mg) and TFA (1.0 eq.) were added. The tube was then sealed and the reaction was allowed to react at 25 ° C for 24 h. After treatment, the crude product was purified by TLC preparation plate to obtain 3ad (38.8 mg, 94% ee, yield: 54%). 1 H NMR (400MHz, CDCl3) δ7.28-7.23(m,2H),7.04-6.98(m,2H),6.89-6.84(m,2H ),6.80(d,J=8.1Hz,1H),5.98(ddd,J=17.3,10.3,4.5Hz,1H),5.25(dt,J=10 .3,1.6Hz,1H),4.95-4.88(m,2H),4.66(dd,J=10.1,1.7Hz,1H),4.13(dd,J= 4.5,2.0Hz,1H),3.92(d,J=13.3Hz,1H),3.80(s,3H),3.74(d,J=13.3Hz,1H). 13 C NMR(101MHz, CDCl3)δ159.1,154.9,139.8,131.0,130.1,130.0,123.4,121.0,119.9,119.2,118.2,113.9,78.2,58.2,55.41,55.38.HRMS(ESI)m / zcalculated for C 18 H 19 BrNO2[M+H] + :360.0594, found: 360.0598. HPLC: Daicel ChiralpakOD-H column (hexane / iPrOH=90:10, flow rate: 1.0mL / min, λ=215nm, t R (major) = 9.22min, t R (minor)=13.57min.ee=92%.

[0043] Implementation Example 5:

[0044] Synthesis of (3ae):

[0045]

[0046] Under argon protection, 1,5-cyclooctadiene iridium chloride dimer (5.3 mg, 4 mol%), (S)-L (16.6 mg, 16 mol%) and dichloroethane (1.5 mL) were added to the reaction tube and stirred at room temperature for 10 minutes. Subsequently, 1e (0.2 mmol, 44.0 mg, 1 eq.), 2a (0.1 mmol, 44.6 mg) and TFA (1.0 eq.) were added. The tube was then sealed and the reaction was allowed to react at 25 ° C for 24 h. After treatment, the crude product was purified by TLC preparation plate to obtain 3ae (28.1 mg, 95% ee, yield: 40%). 1 H NMR (400MHz, CDCl3) δ7.29-7.23(m,3H),6.91-6.84(m,3H),5.96(ddd,J=17.3 ,10.4,4.5Hz,1H),5.29(ddd,J=10.3,1.8,1.1Hz,1H),5.00(d,J=10.1Hz,1H) ,4.94(ddd,J=17.3,1.9,1.2Hz,1H),4.87(dd,J=10.1,1.7Hz,1H),4.15(dd,J =4.4,2.0Hz,1H),3.96(d,J=13.4Hz,1H),3.81(s,3H),3.72(d,J=13.5Hz,1H). 13 C NMR (101MHz, CDCl3) δ159.2,148.7,139.2,130.0,129.6,128.5,127.8,124.6,122.9,122.1,118.7,114.0,79.4,58.1,55.6,55.4.HRMS(ESI)m / zcalculated for C 18 H 18 Cl2NO2[M+H] + :350.0709, found: 30.0703. HPLC: Daicel ChiralpakOJ-H column (hexane / iPrOH=90:10, flow rate: 1.0mL / min, λ=215nm, t R (major)=6.74min,t R (minor)=10.49min.ee=95%.

[0047] Implementation Example 6:

[0048] Synthesis of (3af):

[0049]

[0050] Under argon protection, 1,5-cyclooctadiene iridium chloride dimer (5.3 mg, 4 mol%), (S)-L (16.6 mg, 16 mol%) and dichloroethane (1.5 mL) were added to the reaction tube and stirred at room temperature for 10 minutes. Subsequently, 1f (0.2 mmol, 41.0 mg, 1 eq.), 2a (0.1 mmol, 44.6 mg) and TFA (1.0 eq.) were added. The tube was then sealed and the reaction was allowed to react at 25 ° C for 24 h. After treatment, the crude product was purified by TLC preparation plate to obtain 3ae (29.0 mg, 86% ee, yield: 43%). 1 H NMR (400MHz, CDCl3) δ7.31-7.26(m,2H),7.17(dd,J=5.9,3.6Hz,1H),6.90-6.79(m,4 H), 6.05 (ddd, J=17.2, 10.3, 4.8Hz, 1H), 5.22 (dt, J=10.3, 1.7Hz, 1H), 5.03 (dt, J=17. 2,1.7Hz,1H),4.87(d,J=10.0Hz,1H),4.68(dd,J=10.0,1.8Hz,1H),4.18(dd,J=4.7, 2.0Hz,1H),3.91(d,J=13.1Hz,1H),3.80(s,3H),3.76(d,J=13.1Hz,1H),1.40(s,9H). 13 C NMR (101MHz, CDCl3) δ159.0,153.0,140.7,137.6,130.5,130.3,127.7,125.1, 120.3,119.4,117.2,113.9,76.8,59.6,55.4,55.3,34.9,29.7.HRMS(ESI)m / z calculated for C 20 H 28 NO2[M+H] + :338.2115,found:338.2121.HPLC:Daicel Chiralpak IB column(hexane / iPrOH=95:5, flow rate:1.0mL / min,λ=215nm,t R (major)=6.60min,t R (minor) = 6.24min.ee = 86%. Implementation Example 7:

[0051] Synthesis of (3ag):

[0052]

[0053] Under argon protection, 1,5-cyclooctadiene iridium chloride dimer (5.3 mg, 4 mol%), (S)-L (16.6 mg, 16 mol%) and dichloroethane (1.5 mL) were added to the reaction tube and stirred at room temperature for 10 minutes. Subsequently, 1a (0.2 mmol, 30.0 mg, 1 eq.), 2a (0.1 mmol, 36.6 mg) and TFA (1.0 eq.) were added. The tube was then sealed and the reaction was allowed to react at 25 ° C for 24 h. After treatment, the crude product was purified by TLC preparation plate to obtain 3ae (32.0 mg, 96% ee, yield: 63%). 1 H NMR (400MHz, CDCl3) δ7.40-7.17(m,5H),7.13-7.00(m,1H),6.88(dd,J=7.6,1.8Hz,1H),6.84-6.73(m,2H),5.97(ddd,J=17.2,10.3,4.6Hz,1H),5.18 (dt,J=10.3,1.7Hz,1H),5.01-4.83(m,2H),4.61(dd,J=10.1,1.7Hz,1H),4 .11(dd,J=4.6,2.0Hz,1H),3.97(d,J=13.7Hz,1H),3.78(d,J=13.8Hz,1H). 13 C NMR (100MHz, CDCl3) δ152.92,139.10,137.30,128.63,127.66,127.38,127.02,126.28,119.29,119.15,116.57,115.64,77.06,57.67,54.90.

[0054] HRMS(ESI)m / z calculated for C 17 H 18 NO[M+H] + :252.1383, found:252.1386.HPLC: Daicel Chiralpak OJ-H column (hexane / iPrOH=90:10, flow rate: 0.9mL / min, λ=215nm, t R (major)=6.74min,t R (minor)=10.49min.ee=96%.

[0055] The following examples 8-12 are controlled variable experiments:

[0056] Implementation Example 8 (Variation of Catalyst Amount):

[0057] Synthesis of (3aa)

[0058] Under argon protection, 1,5-cyclooctadiene iridium chloride dimer (2.6 mg, 2 mol%), (S)-L (8.8 mg, 8 mol%) and dichloroethane (1.5 mL) were added to the reaction tube and stirred at room temperature for 10 minutes. Subsequently, 1a (0.2 mmol, 30.0 mg, 1 eq.), 2a (0.1 mmol, 46.6 mg) and TFA (1.0 eq.) were added. The tube was then sealed and the reaction was allowed to react at 0 ° C for 24 h. After treatment, the crude product was purified by TLC preparation plate to obtain 3aa (15.1 mg, 91% ee, yield: 28%).

[0059] Embodiment 9 (reaction solvent change):

[0060] Synthesis of (3aa):

[0061] Under argon protection, 1,5-cyclooctadiene iridium chloride dimer (5.3 mg, 4 mol%), (S)-L (16.6 mg, 16 mol%) and dichloromethane (1.5 mL) were added to the reaction tube and stirred at room temperature for 10 minutes. Subsequently, 1a (0.2 mmol, 30.0 mg, 1 eq.), 2a (0.1 mmol, 44.6 mg) and TFA (1.0 eq.) were added. The tube was then sealed and the reaction was allowed to react at 25 ° C for 24 h. After treatment, the crude product was purified by TLC preparation plate to obtain 3aa (28.1 mg, 92% ee, yield: 50%).

[0062] Embodiment 10 (reaction solvent change):

[0063] Synthesis of (3aa):

[0064] Under argon protection, 1,5-cyclooctadiene iridium chloride dimer (5.3 mg, 4 mol%), (S)-L (16.6 mg, 16 mol%) and toluene (1.5 mL) were added to the reaction tube and stirred at room temperature for 10 minutes. Subsequently, 1a (0.2 mmol, 30.0 mg, 1 eq.), 2a (0.1 mmol, 44.6 mg) and TFA (1.0 eq.) were added. The tube was then sealed and the reaction was allowed to react at 25 ° C for 24 h. After treatment, the crude product was purified by TLC preparation plate to obtain 3aa (8.1 mg, 62% ee, yield: 12%).

[0065] Embodiment 11 (the amount of additive is reduced):

[0066] Synthesis of (3aa):

[0067] Under argon protection, 1,5-cyclooctadiene iridium chloride dimer (5.3 mg, 4 mol%), (S)-L (16.6 mg, 16 mol%) and toluene (1.5 mL) were added to the reaction tube and stirred at room temperature for 10 minutes. Subsequently, 1a (0.2 mmol, 30.0 mg, 1 eq.), 2a (0.1 mmol, 44.6 mg) and TFA (0.5 eq.) were added. The tube was then sealed and the reaction was allowed to react at 25 ° C for 24 h. After treatment, the crude product was purified by TLC preparation plate to obtain 3aa (15.0 mg, 82% ee, yield: 28%).

[0068] Embodiment 12 (additive addition):

[0069] Synthesis of (3aa):

[0070] Under argon protection, 1,5-cyclooctadiene iridium chloride dimer (5.3 mg, 4 mol%), (S)-L (16.6 mg, 16 mol%) and toluene (1.5 mL) were added to the reaction tube and stirred at room temperature for 10 minutes. Subsequently, 1a (0.2 mmol, 30.0 mg, 1 eq.), 2a (0.1 mmol, 44.6 mg) and TFA (1.5 eq.) were added. The tube was then sealed and the reaction was allowed to react at 25 ° C for 24 h. After treatment, the crude product was purified by TLC preparation plate to obtain 3aa (12.2 mg, 86% ee, yield: 16%).

[0071] Implementation Example 13 (1a and 2a equivalence ratio study):

[0072] Synthesis of (3aa):

[0073] Under argon protection, 1,5-cyclooctadiene iridium chloride dimer (8.0 mg, 4 mol%), (S)-L (25 mg, 16 mol%) and dichloroethane (1.5 mL) were added to the reaction tube and stirred at room temperature for 10 minutes. Subsequently, 1a (0.3 mmol, 45.0 mg, 1 eq.), 2a (0.1 mmol, 44.6 mg) and TFA (1.0 eq.) were added. The tube was then sealed and the reaction was allowed to react at 25 ° C for 24 h. After treatment, the crude product was purified by TLC preparation plate to obtain 3aa (36.1 mg, 85% ee, yield: 31%).

[0074] Implementation Example 14 (1a and 2a equivalence ratio study):

[0075] Synthesis of (3aa):

[0076] Under argon protection, 1,5-cyclooctadiene iridium chloride dimer (2.8 mg, 4 mol%), (S)-L (8.4 mg, 16 mol%) and dichloroethane (1.5 mL) were added to the reaction tube and stirred at room temperature for 10 minutes. Subsequently, 1a (0.1 mmol, 15.0 mg, 1 eq.), 2a (0.1 mmol, 44.6 mg) and TFA (1.0 eq.) were added. The tube was then sealed and the reaction was allowed to react at 25 ° C for 24 h. After treatment, the crude product was purified by TLC preparation plate to obtain 3aa (12.7 mg, 70% ee, yield: 45%).

[0077] The embodiments are preferred implementations of the present invention, but the present invention is not limited to the above-mentioned implementations. Any obvious improvements, substitutions or modifications that can be made by those skilled in the art without departing from the essential content of the present invention belong to the protection scope of the present invention.

Claims

1. A method for synthesizing chiral 1,3-benzoxazine derivatives, characterized in that: Under the catalytic action of iridium catalyst, iridium and chiral ligand ( S )-L is fully coordinated, racemic 2-hydroxyphenyl allyl alcohol, 1,3,5-triazine compound and additive trifluoroacetic acid are added, and the racemic 2-hydroxyphenyl allyl alcohol and 1,3,5-triazine compound undergo an asymmetric [4+2]-cycloaddition reaction at 0-40°C to prepare chiral 1,3-benzoxazine derivatives, wherein the structure of the racemic 2-hydroxyphenyl allyl alcohol is: , or , wherein R is hydrogen, methyl, methoxy or halogen; The structural formula of the 1,3,5-triazine compound is: , wherein Ar is phenyl or p-methoxyphenyl; The structural formula of 1,3-benzoxazine derivatives is , or , wherein R is hydrogen, methyl, methoxy or halogen; Ar is phenyl or p-methoxyphenyl; Chiral ligand ( S )-L is: ; The iridium catalyst is 1,5-cyclooctadiene iridium chloride dimer.

2. The method for synthesizing chiral 1,3-benzoxazine derivatives according to claim 1, characterized in that: The method is carried out according to the following steps: under the protection of argon, an iridium catalyst and a chiral ligand are dissolved in a solvent and placed in a sealed tube, and stirred to fully coordinate the iridium and the chiral ligand in the iridium catalyst, and then 2-hydroxyphenyl allyl alcohol, 1,3,5-triazine compound and additive trifluoroacetic acid are added to the sealed tube, argon is replaced, and then fully reacted at 0-40°C, and then purified to obtain a chiral 1,3-benzoxazine derivative; the molar ratio of the 2-hydroxyphenyl allyl alcohol and the 1,3,5-triazine compound is 3:1-1:

1.

3. The method for synthesizing chiral 1,3-benzoxazine derivatives according to claim 2, characterized in that: The temperature should be 25℃.

4. The method for synthesizing chiral 1,3-benzoxazine derivatives according to any one of claim 2, characterized in that: The molar ratio of the 2-hydroxyphenyl allyl alcohol to the 1,3,5-triazine compound is 2:

1.

5. The method for synthesizing chiral 1,3-benzoxazine derivatives according to claim 2, characterized in that: The solvent is any one of dichloromethane, dichloroethane, toluene and chloroform.

6. The method for synthesizing chiral 1,3-benzoxazine derivatives according to claim 2, characterized in that: The dosage of the iridium catalyst is 2%-4% of the molar equivalent of the 1,3,5-triazine compound.

7. A method for synthesizing chiral 1,3-benzoxazine derivatives according to claim 2, wherein the additive amount is 100-400% of the molar equivalent of 1,3,5-triazine.

8. A method for synthesizing chiral 1,3-benzoxazine derivatives according to claim 2, wherein the additive amount is 200% of the molar equivalent of 1,3,5-triazine.

9. A method for synthesizing chiral 1,3-benzoxazine derivatives according to claim 1 or 2, characterized in that: The amount of the chiral ligand used is 200-400% of the molar equivalent of the iridium catalyst.